{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:35:03Z","timestamp":1762522503424,"version":"3.37.3"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA058420","CA164974","CA151135"],"award-info":[{"award-number":["CA058420","CA164974","CA151135"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) has been hypothesized to be associated with reduced risk of breast cancer; however, results of epidemiological studies have been mixed. Few studies have investigated these associations among African American women.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>To assess the relation of aspirin use to risk of breast cancer in African American women, we conducted a prospective analysis within the Black Women\u2019s Health Study, an ongoing nationwide cohort study of 59,000 African American women. On baseline and follow-up questionnaires, women reported regular use of aspirin (defined as use at least 3\u00a0days per week) and years of use. During follow-up from 1995 through 2017, 1919 invasive breast cancers occurred, including 1112 ER+, 569 ER\u2212, and 284 triple-negative (TN) tumors. We used age-stratified Cox proportional hazards regression models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for associations of aspirin use with risk of ER+, ER\u2212, and TN breast cancer, adjusted for established breast cancer risk factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, the HR for current regular use of aspirin relative to non-use was 0.92 (95% CI 0.81, 1.04). For ER+, ER\u2212, and TN breast cancer, corresponding HRs were 0.98 (0.84, 1.15), 0.81 (0.64, 1.04), and 0.70 (0.49, 0.99), respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our findings with regard to ER\u2212 and TN breast cancer are consistent with hypothesized inflammatory mechanisms of ER\u2212 and TN breast cancer, rather than hormone-dependent pathways. Aspirin may represent a potential opportunity for chemoprevention of ER\u2212 and TN breast cancer.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13058-020-01335-1","type":"journal-article","created":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T10:02:57Z","timestamp":1599213777000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Aspirin use and risk of breast cancer in African American women"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4565-7618","authenticated-orcid":false,"given":"Kimberly A.","family":"Bertrand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Traci N.","family":"Bethea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Gerlovin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia F.","family":"Coogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Barber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie R.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,4]]},"reference":[{"issue":"3","key":"1335_CR1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1023\/A:1016361932220","volume":"74","author":"KC Chu","year":"2002","unstructured":"Chu KC, Anderson WF. Rates for breast cancer characteristics by estrogen and progesterone receptor status in the major racial\/ethnic groups. Breast Cancer Res Treat. 2002;74(3):199\u2013211.","journal-title":"Breast Cancer Res Treat"},{"issue":"14","key":"1335_CR2","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1093\/jnci\/djs264","volume":"104","author":"CA Clarke","year":"2012","unstructured":"Clarke CA, Keegan TH, Yang J, Press DJ, Kurian AW, Patel AH, Lacey JV Jr. Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. J Natl Cancer Inst. 2012;104(14):1094\u2013101.","journal-title":"J Natl Cancer Inst"},{"key":"1335_CR3","doi-asserted-by":"crossref","unstructured":"Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, Cronin KA. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5):dju055.","DOI":"10.1093\/jnci\/dju055"},{"issue":"3","key":"1335_CR4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3322\/caac.21555","volume":"69","author":"CE DeSantis","year":"2019","unstructured":"DeSantis CE, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Cancer statistics for African Americans, 2019. CA Cancer J Clin. 2019;69(3):211\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"1335_CR5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2174\/187152006776930873","volume":"6","author":"ES Diaz-Cruz","year":"2006","unstructured":"Diaz-Cruz ES, Brueggemeier RW. Interrelationships between cyclooxygenases and aromatase: unraveling the relevance of cyclooxygenase inhibitors in breast cancer. Anti Cancer Agents Med Chem. 2006;6(3):221\u201332.","journal-title":"Anti Cancer Agents Med Chem"},{"issue":"5","key":"1335_CR6","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/annonc\/mdf125","volume":"13","author":"G Davies","year":"2002","unstructured":"Davies G, Martin LA, Sacks N, Dowsett M. Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann Oncol. 2002;13(5):669\u201378.","journal-title":"Ann Oncol"},{"issue":"4","key":"1335_CR7","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/bcr1678","volume":"9","author":"LR Howe","year":"2007","unstructured":"Howe LR. Inflammation and breast cancer. Cyclooxygenase\/prostaglandin signaling and breast cancer. Breast Cancer Res. 2007;9(4):210.","journal-title":"Breast Cancer Res"},{"issue":"12","key":"1335_CR8","doi-asserted-by":"crossref","first-page":"814","DOI":"10.7326\/M15-2117","volume":"164","author":"J Chubak","year":"2016","unstructured":"Chubak J, Whitlock EP, Williams SB, Kamineni A, Burda BU, Buist DS, Anderson ML. Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. preventive services task force. Ann Intern Med. 2016;164(12):814\u201325.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1335_CR9","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s12885-018-4156-5","volume":"18","author":"Y Qiao","year":"2018","unstructured":"Qiao Y, Yang T, Gan Y, Li W, Wang C, Gong Y, Lu Z. Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies. BMC Cancer. 2018;18(1):288.","journal-title":"BMC Cancer"},{"issue":"25","key":"1335_CR10","doi-asserted-by":"crossref","first-page":"40389","DOI":"10.18632\/oncotarget.16315","volume":"8","author":"L Lu","year":"2017","unstructured":"Lu L, Shi L, Zeng J, Wen Z. Aspirin as a potential modality for the chemoprevention of breast cancer: a dose-response meta-analysis of cohort studies from 857,831 participants. Oncotarget. 2017;8(25):40389\u2013401.","journal-title":"Oncotarget"},{"issue":"11","key":"1335_CR11","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s10552-011-9832-6","volume":"22","author":"JL Bosco","year":"2011","unstructured":"Bosco JL, Palmer JR, Boggs DA, Hatch EE, Rosenberg L. Regular aspirin use and breast cancer risk in US Black women. Cancer Causes Control. 2011;22(11):1553\u201361.","journal-title":"Cancer Causes Control"},{"issue":"2","key":"1335_CR12","first-page":"56","volume":"50","author":"L Rosenberg","year":"1995","unstructured":"Rosenberg L, Adams-Campbell L, Palmer JR. The Black Women\u2019s Health Study: a follow-up study for causes and preventions of illness. J Am Med Womens Assoc. 1995;50(2):56\u20138.","journal-title":"J Am Med Womens Assoc"},{"issue":"S1","key":"1335_CR13","first-page":"S168","volume":"12","author":"KE Kelley","year":"2003","unstructured":"Kelley KE, Kelley TP, Kaufman DW, Mitchell AA. The Slone Drug Dictionary: a research driven pharmacoepidemiology tool. Pharmacoepidemiol Drug Saf. 2003;12(S1):S168\u201398.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"1335_CR14","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/sim.6793","volume":"35","author":"M Wang","year":"2016","unstructured":"Wang M, Spiegelman D, Kuchiba A, Lochhead P, Kim S, Chan AT, Poole EM, Tamimi R, Tworoger SS, Giovannucci E, et al. Statistical methods for studying disease subtype heterogeneity. Stat Med. 2016;35(5):782\u2013800.","journal-title":"Stat Med"},{"issue":"11","key":"1335_CR15","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1158\/1055-9965.EPI-15-0452","volume":"24","author":"S Zhong","year":"2015","unstructured":"Zhong S, Chen L, Zhang X, Yu D, Tang J, Zhao J. Aspirin use and risk of breast cancer: systematic review and meta-analysis of observational studies. Cancer Epidemiol Biomark Prev. 2015;24(11):1645\u201355.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"1","key":"1335_CR16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13058-017-0840-7","volume":"19","author":"CA Clarke","year":"2017","unstructured":"Clarke CA, Canchola AJ, Moy LM, Neuhausen SL, Chung NT, Lacey JV Jr, Bernstein L. Regular and low-dose aspirin, other non-steroidal anti-inflammatory medications and prospective risk of HER2-defined breast cancer: the California Teachers Study. Breast Cancer Res. 2017;19(1):52.","journal-title":"Breast Cancer Res"},{"issue":"11","key":"1335_CR17","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/jnci\/dji140","volume":"97","author":"SF Marshall","year":"2005","unstructured":"Marshall SF, Bernstein L, Anton-Culver H, Deapen D, Horn-Ross PL, Mohrenweiser H, Peel D, Pinder R, Purdie DM, Reynolds P, et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst. 2005;97(11):805\u201312.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1335_CR18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10549-010-1074-x","volume":"126","author":"A Bardia","year":"2011","unstructured":"Bardia A, Olson JE, Vachon CM, Lazovich D, Vierkant RA, Wang AH, Limburg PJ, Anderson KE, Cerhan JR. Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Res Treat. 2011;126(1):149\u201355.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"1335_CR19","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s10549-007-9665-x","volume":"109","author":"A Ready","year":"2008","unstructured":"Ready A, Velicer CM, McTiernan A, White E. NSAID use and breast cancer risk in the VITAL cohort. Breast Cancer Res Treat. 2008;109(3):533\u201343.","journal-title":"Breast Cancer Res Treat"},{"issue":"18","key":"1335_CR20","first-page":"6096","volume":"63","author":"RE Harris","year":"2003","unstructured":"Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, Anderson G, Loar A, Rodabough RJ, White E, McTiernan A. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women\u2019s Health Initiative. Cancer Res. 2003;63(18):6096\u2013101.","journal-title":"Cancer Res"},{"issue":"2","key":"1335_CR21","doi-asserted-by":"crossref","first-page":"R38","DOI":"10.1186\/bcr2089","volume":"10","author":"GL Gierach","year":"2008","unstructured":"Gierach GL, Lacey JV Jr, Schatzkin A, Leitzmann MF, Richesson D, Hollenbeck AR, Brinton LA. Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study. Breast Cancer Res. 2008;10(2):R38.","journal-title":"Breast Cancer Res"},{"key":"1335_CR22","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1186\/s12885-015-1979-1","volume":"15","author":"S Kim","year":"2015","unstructured":"Kim S, Shore DL, Wilson LE, Sanniez EI, Kim JH, Taylor JA, Sandler DP. Lifetime use of nonsteroidal anti-inflammatory drugs and breast cancer risk: results from a prospective study of women with a sister with breast cancer. BMC Cancer. 2015;15:960.","journal-title":"BMC Cancer"},{"issue":"28","key":"1335_CR23","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1200\/JCO.2012.42.2006","volume":"30","author":"X Zhang","year":"2012","unstructured":"Zhang X, Smith-Warner SA, Collins LC, Rosner B, Willett WC, Hankinson SE. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. J Clin Oncol. 2012;30(28):3468\u201377.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1335_CR24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1001\/archinternmed.2008.537","volume":"169","author":"AH Eliassen","year":"2009","unstructured":"Eliassen AH, Chen WY, Spiegelman D, Willett WC, Hunter DJ, Hankinson SE. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses\u2019 Health Study II. Arch Intern Med. 2009;169(2):115\u201321 discussion 121.","journal-title":"Arch Intern Med"},{"issue":"6","key":"1335_CR25","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1001\/jamaoncol.2015.6396","volume":"2","author":"Y Cao","year":"2016","unstructured":"Cao Y, Nishihara R, Wu K, Wang M, Ogino S, Willett WC, Spiegelman D, Fuchs CS, Giovannucci EL, Chan AT. Population-wide impact of long-term use of aspirin and the risk for cancer. JAMA Oncol. 2016;2(6):762\u20139.","journal-title":"JAMA Oncol"},{"issue":"10","key":"1335_CR26","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/aje\/kwm195","volume":"166","author":"JK Gill","year":"2007","unstructured":"Gill JK, Maskarinec G, Wilkens LR, Pike MC, Henderson BE, Kolonel LN. Nonsteroidal antiinflammatory drugs and breast cancer risk: the multiethnic cohort. Am J Epidemiol. 2007;166(10):1150\u20138.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"1335_CR27","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1158\/1055-9965.261.14.1","volume":"14","author":"EJ Jacobs","year":"2005","unstructured":"Jacobs EJ, Thun MJ, Connell CJ, Rodriguez C, Henley SJ, Feigelson HS, Patel AV, Flanders WD, Calle EE. Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomark Prev. 2005;14(1):261\u20134.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"7","key":"1335_CR28","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/ijc.31570","volume":"143","author":"M Cairat","year":"2018","unstructured":"Cairat M, Fournier A, Murphy N, Biessy C, Scalbert A, Rinaldi S, Tjonneland A, Olsen A, Overvad K, Arveux P, et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk in a European prospective cohort study. Int J Cancer. 2018;143(7):1688\u201395.","journal-title":"Int J Cancer"},{"issue":"2","key":"1335_CR29","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/CEJ.0b013e3282b6fd55","volume":"17","author":"S Friis","year":"2008","unstructured":"Friis S, Thomassen L, Sorensen HT, Tjonneland A, Overvad K, Cronin-Fenton DP, Vogel U, McLaughlin JK, Blot WJ, Olsen JH. Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study. Eur J Cancer Prev. 2008;17(2):88\u201396.","journal-title":"Eur J Cancer Prev"},{"issue":"5","key":"1335_CR30","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.bjc.6604240","volume":"98","author":"SM Zhang","year":"2008","unstructured":"Zhang SM, Cook NR, Manson JE, Lee IM, Buring JE. Low-dose aspirin and breast cancer risk: results by tumour characteristics from a randomised trial. Br J Cancer. 2008;98(5):989\u201391.","journal-title":"Br J Cancer"},{"issue":"1","key":"1335_CR31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.294.1.47","volume":"294","author":"NR Cook","year":"2005","unstructured":"Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE. Low-dose aspirin in the primary prevention of cancer: the Women\u2019s Health Study: a randomized controlled trial. JAMA. 2005;294(1):47\u201355.","journal-title":"JAMA"},{"issue":"10","key":"1335_CR32","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1023\/B:CACO.0000007973.59863.66","volume":"14","author":"PG Moorman","year":"2003","unstructured":"Moorman PG, Grubber JM, Millikan RC, Newman B. Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control. 2003;14(10):915\u201322.","journal-title":"Cancer Causes Control"},{"issue":"4","key":"1335_CR33","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/00001648-200007000-00001","volume":"11","author":"MJ Thun","year":"2000","unstructured":"Thun MJ. Beyond willow bark: aspirin in the prevention of chronic disease. Epidemiology. 2000;11(4):371\u20134.","journal-title":"Epidemiology"},{"issue":"1","key":"1335_CR34","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.steroids.2007.09.011","volume":"73","author":"B Su","year":"2008","unstructured":"Su B, Diaz-Cruz ES, Landini S, Brueggemeier RW. Suppression of aromatase in human breast cells by a cyclooxygenase-2 inhibitor and its analog involves multiple mechanisms independent of cyclooxygenase-2 inhibition. Steroids. 2008;73(1):104\u201311.","journal-title":"Steroids"},{"key":"1335_CR35","doi-asserted-by":"crossref","unstructured":"Gunter MJ, Wang T, Cushman M, Xue X, Wassertheil-Smoller S, Strickler HD, Rohan TE, Manson JE, McTiernan A, Kaplan RC, Scherer PE, Chlebowski RT, Snetselaar L, Wang D, Ho GY. Circulating Adipokines and Inflammatory Markers and Postmenopausal Breast Cancer Risk. J Natl Cancer Inst. 2015;107(9):djv169.","DOI":"10.1093\/jnci\/djv169"},{"issue":"22","key":"1335_CR36","doi-asserted-by":"crossref","first-page":"6462","DOI":"10.1158\/0008-5472.CAN-17-1903","volume":"77","author":"JR Palmer","year":"2017","unstructured":"Palmer JR, Castro-Webb N, Bertrand K, Bethea TN, Denis GV. Type II diabetes and incidence of estrogen receptor negative breast cancer in African American women. Cancer Res. 2017;77(22):6462\u20139.","journal-title":"Cancer Res"},{"issue":"9","key":"1335_CR37","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.2174\/138945010792006799","volume":"11","author":"JE Goldberg","year":"2010","unstructured":"Goldberg JE, Schwertfeger KL. Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr Drug Targets. 2010;11(9):1133\u201346.","journal-title":"Curr Drug Targets"},{"issue":"5","key":"1335_CR38","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1188\/13.ONF.40-05AP","volume":"40","author":"NJ Park","year":"2013","unstructured":"Park NJ, Kang DH. Inflammatory cytokine levels and breast cancer risk factors: racial differences of healthy Caucasian and African American women. Oncol Nurs Forum. 2013;40(5):490\u2013500.","journal-title":"Oncol Nurs Forum"},{"issue":"6","key":"1335_CR39","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/ijc.28458","volume":"134","author":"L Quan","year":"2014","unstructured":"Quan L, Gong Z, Yao S, Bandera EV, Zirpoli G, Hwang H, Roberts M, Ciupak G, Davis W, Sucheston L, et al. Cytokine and cytokine receptor genes of the adaptive immune response are differentially associated with breast cancer risk in American women of African and European ancestry. Int J Cancer. 2014;134(6):1408\u201321.","journal-title":"Int J Cancer"},{"issue":"3\u20134","key":"1335_CR40","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10911-015-9333-4","volume":"20","author":"HJ Hugo","year":"2015","unstructured":"Hugo HJ, Saunders C, Ramsay RG, Thompson EW. New insights on COX-2 in chronic inflammation driving breast cancer growth and metastasis. J Mammary Gland Biol Neoplasia. 2015;20(3\u20134):109\u201319.","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"1335_CR41","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1186\/1471-2407-10-626","volume":"10","author":"SA Glynn","year":"2010","unstructured":"Glynn SA, Prueitt RL, Ridnour LA, Boersma BJ, Dorsey TM, Wink DA, Goodman JE, Yfantis HG, Lee DH, Ambs S. COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer. BMC Cancer. 2010;10:626.","journal-title":"BMC Cancer"},{"issue":"3","key":"1335_CR42","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.cyto.2011.09.013","volume":"56","author":"TV Clendenen","year":"2011","unstructured":"Clendenen TV, Koenig KL, Arslan AA, Lukanova A, Berrino F, Gu Y, Hallmans G, Idahl A, Krogh V, Lokshin AE, et al. Factors associated with inflammation markers, a cross-sectional analysis. Cytokine. 2011;56(3):769\u201378.","journal-title":"Cytokine"},{"issue":"10","key":"1335_CR43","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1158\/1055-9965.EPI-15-0324","volume":"24","author":"DS Chan","year":"2015","unstructured":"Chan DS, Bandera EV, Greenwood DC, Norat T. Circulating C-reactive protein and breast cancer risk-systematic literature review and meta-analysis of prospective cohort studies. Cancer Epidemiol Biomark Prev. 2015;24(10):1439\u201349.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1335_CR44","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1146\/annurev-med-050913-022228","volume":"66","author":"NM Iyengar","year":"2015","unstructured":"Iyengar NM, Hudis CA, Dannenberg AJ. Obesity and cancer: local and systemic mechanisms. Annu Rev Med. 2015;66:297\u2013309.","journal-title":"Annu Rev Med"},{"issue":"10","key":"1335_CR45","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41574-018-0059-4","volume":"14","author":"C Franceschi","year":"2018","unstructured":"Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018;14(10):576\u201390.","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"1335_CR46","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13058-019-1163-7","volume":"21","author":"MM Basree","year":"2019","unstructured":"Basree MM, Shinde N, Koivisto C, Cuitino M, Kladney R, Zhang J, Stephens J, Palettas M, Zhang A, Kim HK, et al. Abrupt involution induces inflammation, estrogenic signaling, and hyperplasia linking lack of breastfeeding with increased risk of breast cancer. Breast Cancer Res. 2019;21(1):80.","journal-title":"Breast Cancer Res"},{"issue":"5","key":"1335_CR47","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000452315","volume":"11","author":"D Moris","year":"2016","unstructured":"Moris D, Kontos M, Spartalis E, Fentiman IS. The role of NSAIDs in breast cancer prevention and relapse: current evidence and future perspectives. Breast care (Basel, Switzerland). 2016;11(5):339\u201344.","journal-title":"Breast care (Basel, Switzerland)"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-020-01335-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-020-01335-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-020-01335-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T15:55:14Z","timestamp":1668614114000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-020-01335-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,4]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1335"],"URL":"https:\/\/doi.org\/10.1186\/s13058-020-01335-1","relation":{},"ISSN":["1465-542X"],"issn-type":[{"type":"electronic","value":"1465-542X"}],"subject":[],"published":{"date-parts":[[2020,9,4]]},"assertion":[{"value":"21 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Boston University Institutional Review Board. Consent to participate was implied by return of the baseline questionnaire.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"96"}}